Also listed on Horizon Pharma Rheumatology LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jun 25, 2030 · High confidence
20-year base term ends Jun 25, 2030
Jun 25, 2010
Jun 25, 2030
May 2, 2023
This patent's term runs 166 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 1 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 25, 2010, when applications PCT/US2010/004008 and PCT/US2010/040082, the earliest non-provisional applications in its chain, were filed (this one was filed Sep 29, 2020) | Jun 25, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +166 days, USPTO patent term adjustment record | Dec 8, 2030 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,139,399, US 10,823,727, US 9,377,454) | capped to Jun 25, 2030 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 25, 2030 | High confidence |
Partial family
| Application PCT/US2010/004008 | PCT application no patent term | no patent term |
| Application PCT/US2010/040082 | PCT application no patent term | no patent term |
| US 9,377,454 | In force Jun 2030 | Jun 2030 |
| Application 15/165,318 | Abandoned not computed | not computed |
| US 10,139,399 | In force Jun 2030 | Jun 2030 |
| US 10,823,727 | In force Jun 2030 | Jun 2030 |
| US 11,639,927 | this patent Jun 2030 | Jun 2030 |
| US 11,598,767 | In force Jun 2030 | Jun 2030 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 15, 2021 Reel 55659, frame 430 | Horizon Orphan LLC; Horizon Therapeutics USA, Inc.; Viela Bio, Inc. | Citibank, N.a. | Security Agreement |
| May 27, 2021 Reel 56369, frame 172 | Rosario-jansen, Theresa; Wright, David Erick | Savient Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| May 27, 2021 Reel 56408, frame 201 | Savient Pharmaceuticals, Inc. | Crealta Pharmaceuticals LLC | Assignment of Assignor's Interest |
| May 27, 2021 Reel 56408, frame 238 | Crealta Pharmaceuticals LLC | Horizon Pharma USA Rheumatology LLC | Change of Name |
| May 27, 2021 Reel 56408, frame 241 | Horizon Pharma USA Rheumatology LLC | Horizon Pharma Rheumatology LLC | Change of Name |
| Dec 13, 2022 Reel 62117, frame 155 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Assignment of Assignor's Interest |
| Oct 6, 2023 Reel 65154, frame 64 | Citibank, N.a. | Horizon Therapeutics U.S. Holding LLC (FKA Horizon Orphan LLC); Horizon Therapeutics USA, Inc.; Viela Bio, Inc. | Release of Security Interest |
| Oct 6, 2023 reel/frame not recorded | Citibank, N.a. | Horizon Therapeutics U.S. Holding LLC (FKA Horizon Orphan LLC) | Release of Security Interest |
| Oct 6, 2023 reel/frame not recorded | Citibank, N.a. | Horizon Therapeutics USA, Inc. | Release of Security Interest |
| Oct 6, 2023 reel/frame not recorded | Citibank, N.a. | Viela Bio, Inc. | Release of Security Interest |
| Nov 6, 2026 Reel 76662, frame 840 | Horizon Therapeutics USA, Inc. | Horizon Therapeutics Ireland Dac | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,139,399, US 10,823,727, US 9,377,454.